Corrie Berk,

DNP, MBA, APRN

Corrie Berk,

DNP, MBA, APRN
Nurse Practitioner, Texas Liver Institute

Corrie Berk,

DNP, MBA, APRN
Nurse Practitioner, Texas Liver Institute
Corrie Berk, DNP, MBA, APRN, is a board-certified family nurse practitioner with Texas Liver Institute (TLI) as director of Hepatology and Transplant Outreach Programs. Clinically, she practices at TLI’s several outreach clinics throughout central and southern Texas. She is chair of the American Association for the Study of Liver Diseases (AASLD) Hepatology Associates Committee and serves on the Scientific Programming Committees for both The Liver Meeting and Digestive Disease Week. She was the recipient of the 2019 AASLD Mid-Career Hepatology Associate Scholar Award and the 2021 recipient of the American Society of Transplant Surgeons’ Advanced Transplant Provider Award. She earned all degrees and received training at the University of Pittsburgh and University of Pittsburgh Medical Center.

Corrie's Shared Resources

Liver Biopsy Evaluation in MASH

During recent decades, the metabolic dysfunction-associated steatohepatitis (MASH) field has witnessed several paradigm shifts, including the recognition of liver fibrosis...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN
Medications stacked on a pharmacy counter, ready to be sold. Represents a typical scene in the daily routine of a pharmacy

Advancements in MASLD Diagnosis: Non-Invasive Tools

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NASH, is a growing health concern due to its association with...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN

GLP-1 Agonists’ Potential for Fibrosis Regression

In a recent review, researchers examined the molecular and clinical effects of glucagon-like peptide 1 (GLP-1) receptor agonists in treating...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Detecting Significant Fibrosis in Hispanic Patients With MASLD

A recent study evaluated the performance of noninvasive tests (NITs) for detecting significant fibrosis in Hispanic patients with metabolic dysfunction–associated...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Resmetirom and Advanced Liver Fibrosis

Resmetirom (MGL-3196) received accelerated FDA approval in March 2024 for treating MASH with moderate to advanced liver fibrosis (F2-F3). This...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Resmetirom FDA-Approved for MASH

In 2024, resmetirom (MGL-3196) became the first FDA-approved drug for MASH, demonstrating significant efficacy in resolving MASH without worsening fibrosis...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN
Share